Bayer vs Johnson & Johnson

Streuplan Creates Three TV Spots for Bayer Switzerland

The Swiss agency Streuplan has developed a summer campaign for Bayer Schweiz to promote Bepanthen MED Plus. The campaign's centerpiece is three TV spots depicting a hiking family encountering minor mishaps, which alter their planned excursion. Each spot addresses a different everyday situation: differing parenting views, excessive smartphone use, and a runaway cheese disrupting a photo session. The films aired on TV channels across German-speaking Switzerland, French-speaking Switzerland, and Ticino, targeting relevant audiences. The production was shot over two days in Morschach, Switzerland, with Salient Media handling production and Nicholas Beyeler directing. Both long and short TV versions were created, along with adaptations for social media in landscape and portrait formats. A key visual for point-of-sale communications was also produced. The campaign ran during the summer across all three language regions.

• Streuplan created a summer campaign for Bayer Schweiz promoting Bepanthen MED Plus.
• The campaign consists of three TV spots showing a hiking family experiencing minor mishaps.
• The spots aired on TV channels in German, French, and Italian speaking regions of Switzerland.

German Companies Cut Thousands of Management Jobs

German corporations are eliminating thousands of management positions, particularly in the middle management layer between C-suite and operational business. Volkswagen plans to cut about 5,000 of its 21,500 management roles worldwide, BMW is reducing leadership levels, and BASF has already shed 11% of its managers in the past two years. In 2025, a record 49,000 executives were unemployed. Bayer CEO Bill Anderson is spearheading a radical restructuring, aiming to eliminate up to 12,000 of roughly 17,000 leadership positions by flattening the corporate hierarchy from twelve levels. This trend is driven by weak economic conditions, high transformation costs, and a desire for leaner, faster organizations. Affected managers face not only financial uncertainty but also loss of status and identity, and re-entering the job market is challenging as companies now prioritize operational experience, technology skills, and change management capability.

• Volkswagen plans to cut approximately 5,000 of its 21,500 management positions worldwide.
• BASF has reduced its leadership workforce by 11% over the past two years.
• A record 49,000 executives were registered as unemployed in Germany in 2025.

Iberogast's Big Screen YouTube Strategy Boosts Reach by 17 Points

At the YouTube Festival 2026, Bayer's Consumer Health brand Iberogast presented a case study on shifting TV budget to YouTube to reach younger audiences. Facing an awareness gap among 25-44 year-olds, Bayer used Google's DV360 Reach Planner to model an integrated cross-media plan. The recommendation was to shift 30% of the TV budget to YouTube, targeting Connected TV (Big Screen) with non-skippable ads. The campaign achieved a net reach of 67%, 17 percentage points higher than a pure TV campaign, exactly as predicted. Brand Lift data showed a 41% increase in ad recall and a 7% increase in purchase intent. This pilot has become the new standard for Bayer Consumer Health, which now orchestrates a holistic Big Screen strategy across its brand portfolio, planning linear TV and YouTube together.

• Bayer shifted 30% of Iberogast's TV budget to YouTube as recommended by Google's DV360 Reach Planner.
• The campaign reached 67% net reach in target audience, 17 percentage points higher than a TV-only campaign.
• YouTube reaches 57 million German users monthly, including 20.7 million via Connected TV.

10-Q Financial Filing Analysis for Johnson & Johnson (2026-10-21)

Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.

• Worldwide sales reached $25.40 billion in Q3 2026 (+5.9% YoY) and $74.77 billion for the first nine months (+7.4% YoY), supported by gains in DARZALEX ($4.24 billion in Q3) and TREMFYA ($2.40 billion in Q3).
• Net earnings plummeted to $210 million in Q3 2026 due to a $5.5 billion litigation charge to resolve ovarian talc claims and a $1.0 billion acquired IPR&D charge for Firefly Bio, Inc.
• Total present value of reserves for talc-related legal matters reached approximately $9.0 billion as of September 27, 2026, while the planned separation of the Orthopaedics business remains on track for mid-2027.

Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.

A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma

Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy.